Proteases, Mucus, and Mucosal Immunity in Chronic Lung Disease
Dysregulated protease activity has long been implicated in the pathogenesis of chronic lung diseases and especially in conditions that display mucus obstruction, such as chronic obstructive pulmonary disease, cystic fibrosis, and non-cystic fibrosis bronchiectasis. However, our appreciation of the r...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-05-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/9/5018 |
id |
doaj-03931cfe7b8042028b2fda15d87b3de2 |
---|---|
record_format |
Article |
spelling |
doaj-03931cfe7b8042028b2fda15d87b3de22021-05-31T23:31:24ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-05-01225018501810.3390/ijms22095018Proteases, Mucus, and Mucosal Immunity in Chronic Lung DiseaseMichael C. McKelvey0Ryan Brown1Sinéad Ryan2Marcus A. Mall3Sinéad Weldon4Clifford C. Taggart5Airway Innate Immunity Research (AiiR) Group, Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University Belfast, Belfast BT9 7BL, UKAirway Innate Immunity Research (AiiR) Group, Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University Belfast, Belfast BT9 7BL, UKAirway Innate Immunity Research (AiiR) Group, Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University Belfast, Belfast BT9 7BL, UKDepartment of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité—Universitätsmedizin Berlin, 13353 Berlin, GermanyAirway Innate Immunity Research (AiiR) Group, Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University Belfast, Belfast BT9 7BL, UKAirway Innate Immunity Research (AiiR) Group, Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University Belfast, Belfast BT9 7BL, UKDysregulated protease activity has long been implicated in the pathogenesis of chronic lung diseases and especially in conditions that display mucus obstruction, such as chronic obstructive pulmonary disease, cystic fibrosis, and non-cystic fibrosis bronchiectasis. However, our appreciation of the roles of proteases in various aspects of such diseases continues to grow. Patients with muco-obstructive lung disease experience progressive spirals of inflammation, mucostasis, airway infection and lung function decline. Some therapies exist for the treatment of these symptoms, but they are unable to halt disease progression and patients may benefit from novel adjunct therapies. In this review, we highlight how proteases act as multifunctional enzymes that are vital for normal airway homeostasis but, when their activity becomes immoderate, also directly contribute to airway dysfunction, and impair the processes that could resolve disease. We focus on how proteases regulate the state of mucus at the airway surface, impair mucociliary clearance and ultimately, promote mucostasis. We discuss how, in parallel, proteases are able to promote an inflammatory environment in the airways by mediating proinflammatory signalling, compromising host defence mechanisms and perpetuating their own proteolytic activity causing structural lung damage. Finally, we discuss some possible reasons for the clinical inefficacy of protease inhibitors to date and propose that, especially in a combination therapy approach, proteases represent attractive therapeutic targets for muco-obstructive lung diseases.https://www.mdpi.com/1422-0067/22/9/5018chronic lung diseaseproteasesantiproteasesmucusmuco-obstructive lung diseasemucociliary clearance |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Michael C. McKelvey Ryan Brown Sinéad Ryan Marcus A. Mall Sinéad Weldon Clifford C. Taggart |
spellingShingle |
Michael C. McKelvey Ryan Brown Sinéad Ryan Marcus A. Mall Sinéad Weldon Clifford C. Taggart Proteases, Mucus, and Mucosal Immunity in Chronic Lung Disease International Journal of Molecular Sciences chronic lung disease proteases antiproteases mucus muco-obstructive lung disease mucociliary clearance |
author_facet |
Michael C. McKelvey Ryan Brown Sinéad Ryan Marcus A. Mall Sinéad Weldon Clifford C. Taggart |
author_sort |
Michael C. McKelvey |
title |
Proteases, Mucus, and Mucosal Immunity in Chronic Lung Disease |
title_short |
Proteases, Mucus, and Mucosal Immunity in Chronic Lung Disease |
title_full |
Proteases, Mucus, and Mucosal Immunity in Chronic Lung Disease |
title_fullStr |
Proteases, Mucus, and Mucosal Immunity in Chronic Lung Disease |
title_full_unstemmed |
Proteases, Mucus, and Mucosal Immunity in Chronic Lung Disease |
title_sort |
proteases, mucus, and mucosal immunity in chronic lung disease |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1661-6596 1422-0067 |
publishDate |
2021-05-01 |
description |
Dysregulated protease activity has long been implicated in the pathogenesis of chronic lung diseases and especially in conditions that display mucus obstruction, such as chronic obstructive pulmonary disease, cystic fibrosis, and non-cystic fibrosis bronchiectasis. However, our appreciation of the roles of proteases in various aspects of such diseases continues to grow. Patients with muco-obstructive lung disease experience progressive spirals of inflammation, mucostasis, airway infection and lung function decline. Some therapies exist for the treatment of these symptoms, but they are unable to halt disease progression and patients may benefit from novel adjunct therapies. In this review, we highlight how proteases act as multifunctional enzymes that are vital for normal airway homeostasis but, when their activity becomes immoderate, also directly contribute to airway dysfunction, and impair the processes that could resolve disease. We focus on how proteases regulate the state of mucus at the airway surface, impair mucociliary clearance and ultimately, promote mucostasis. We discuss how, in parallel, proteases are able to promote an inflammatory environment in the airways by mediating proinflammatory signalling, compromising host defence mechanisms and perpetuating their own proteolytic activity causing structural lung damage. Finally, we discuss some possible reasons for the clinical inefficacy of protease inhibitors to date and propose that, especially in a combination therapy approach, proteases represent attractive therapeutic targets for muco-obstructive lung diseases. |
topic |
chronic lung disease proteases antiproteases mucus muco-obstructive lung disease mucociliary clearance |
url |
https://www.mdpi.com/1422-0067/22/9/5018 |
work_keys_str_mv |
AT michaelcmckelvey proteasesmucusandmucosalimmunityinchroniclungdisease AT ryanbrown proteasesmucusandmucosalimmunityinchroniclungdisease AT sineadryan proteasesmucusandmucosalimmunityinchroniclungdisease AT marcusamall proteasesmucusandmucosalimmunityinchroniclungdisease AT sineadweldon proteasesmucusandmucosalimmunityinchroniclungdisease AT cliffordctaggart proteasesmucusandmucosalimmunityinchroniclungdisease |
_version_ |
1721417242162233344 |